Sign inJoin waitlistJoin the waitlist

Ki Chung

Associate Professor · University of South Carolina-Columbia

Credentials: · · · ·

History

University of South Carolina-Columbia
Present

Medical Oncology
1998–2000
Internal Medicine
1995–1998
University of North Carolina at Chapel Hill School of Medicine
1991–1995

Research

Cetuximab shows activity in colorectal cancer patients with tumors that do not express the epidermal growth factor receptor by immunohistochemistry
Journal of Clinical Oncology · 2005 · First of 14 authors · Corresponding · 904 citations
Trastuzumab deruxtecan (DS-8201) in patients with HER2-expressing metastatic colorectal cancer (DESTINY-CRC01): a multicentre, open-label, phase 2 trial
The Lancet Oncology · 2021 · 355 citations
ctDNA applications and integration in colorectal cancer: an NCI Colon and Rectal-Anal Task Forces whitepaper
Review · Nature Reviews Clinical Oncology · 2020 · 305 citations

LS
Leonard Saltz
8 papers
DK
David Kelsen
5 papers
DK
David Klimstra
3 papers
DS
Deb Schrag
3 papers
EO
Eileen O'Reilly
3 papers
JS
Jinru Shia
3 papers
William Edenfield
3 papers
Alan Venook
2 papers
AT
Archie Tse
2 papers
Arvind Dasari
2 papers
Bradley Monk
2 papers
David O'Malley
2 papers

Grants

NCORP of the Carolinas (Greenville Health System NCORP)
National Cancer Institute · UG1
Contact PI · $11.2M · Prisma Health - Upstate
2014–2027

Clinical trials

Phase II Study of Tazemetostat in Solid Tumors Harboring an ARID1A Mutation
Principal investigator · Terminated · Phase 2
Prisma Health-Upstate
2022–2026
Oblimersen in Treating Patients With Merkel Cell Carcinoma
Principal investigator · Completed · Phase 2
National Cancer Institute (NCI)
2004
A Study of IDRX-42 (GSK6042981) Versus (vs) Sunitinib in Participants With Gastrointestinal Stromal Tumors After Imatinib Therapy
Site PI · Recruiting · Phase 3
GlaxoSmithKline
2025–2030
Using Biomarker Tests to Select and Test New, Personalized Treatments for Extensive Stage Small Cell Lung Cancer, PRISM Study
Site PI · Recruiting · Phase 2
SWOG Cancer Research Network
2025–2029